hotspot -WSS

hotspot

author：Wikipedia 2025-10-02 22:56:24 - browse：4896

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Many immigrants are left out of maternal health programs

WSS

Melinda French Gates resigns from Gates Foundation

H5N1 bird flu found in pasteurized milk: what we know

FTC falls short on scrutinizing hospital mergers, study says

Trump team launching legal defense fund to help pay legal bills

Health care needs a new profession: neuroimaging counseling

Cell therapy fails to slow type 1 diabetes, but safety is established

focus

hotspot

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Snowpack in the West is melting rapidly. Where will all that extra water go?

Activists slam private health insurers over coverage restrictions

More tobacco lobbyists active in statehouses

Guidelines to prevent youth baseball injuries need more muscle

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

After affirmative action ruling, medical educators look to 'holistic review'

'Weather

Moonlake's readout produced a cash windfall. Risks remain

H5N1 bird flu found in pasteurized milk: what we know

knowledge

Campaign finance charge dropped from case against Sam Bankman

What AstraZeneca

Many immigrants are left out of maternal health programs

Doctors increasingly discourage vaping amid mounting health concerns

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

focus

focus

knowledge

hotspot